Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27521450.
- Also identified by PMC identifier 5093093.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. Clin Cancer Res; 22(21); 5164-6. ©2016 AACRSee related article by Yoo et al., p. 5265.
Medical subject headings
- Antineoplastic Agents
- Bortezomib
- Glioblastoma
- Herpesvirus 1, Human
- Killer Cells, Natural
- Oncolytic Viruses